Business Wire

U.S. Voter Behavior Dominated by Relief and Disgust – Study by NayaDaya

23.9.2020 15:00:00 EEST | Business Wire | Press release

Share

Study on the presidential election, conducted by NayaDaya, YouGov, and Statista, shows that U.S. citizens will vote to prevent the undesirable from happening.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005036/en/

The study reveals emotions and behavior of U.S. citizens, evoked by the election of Trump and Pence or Biden and Harris. The most chosen emotions are relief, disgust, fear, and disappointment – distribution varies between candidates.

“For U.S. voters the election is mostly about avoiding an undesirable result, not about being emotionally uplifted by the candidates,” says Marcello Mortillaro, Ph.D and Senior Scientist, Partner of NayaDaya Inc.

The most chosen emotion for Trump’s re-election is disengaging disgust that indicates violating voters’ moral standards. Pence is Trump’s reflection: His re-election evokes even more disgust but overall less emotions. In Biden’s case, the most common emotion is relief, implying avoidance of a threat.

Mortillaro explains: “As for Biden, almost half of Democrats feel relief, a positive emotion with a low engaging impact. Harris is unlike Biden. She arouses positive, engaging emotions of pride, admiration and joy.” Among Republicans, disgust and fear are the strongest emotions toward both Harris’ and Biden’s elections.

The NayaDaya® Emotional and Behavioral Intelligence, which is based on scientific research independently conducted by the University of Geneva, Switzerland, was used to analyze the U.S. voter emotions.

Voter emotions predict voter behavior and engagement – percentages for loyals:

  • Trump 32%
  • Pence 27%
  • Biden 45%
  • Harris 42%

Among the young (18-34), 47% are loyal to Biden, 27% to Trump. Among the African-Americans, 58% are loyal to Biden, only 13% to Trump. More than a quarter of respondents are not in favor of Democrats or Republicans; 31% of them are positively engaged in Trump, 37% in Biden.

“In the context of significant phenomena like presidential elections, emotions are our key to understanding different perspectives and their behavioral consequences. Through data, insight, empathy, and impact we empower responsible leaders, media, brands, and organizations to thrive and shape the world,” says NayaDaya’s CEO Timo Järvinen.

Study facts:

  • YouGov online panel Sept 2-4, 2020
  • Sample represents U.S. adult population
  • N=1265, margin of error ±2.5 percentage points

Annex: Key findings

Full report and data: www.nayadaya.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts – NayaDaya Inc.
Timo Järvinen, CEO
timo@nayadaya.com
+358 40 505 7745

Timo Salomäki, Head of Global Growth
timos@nayadaya.com
+358 40 709 2399

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release

Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release

Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release

In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release

The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye